Julien Couthouis

The paper shows that reversing age-related changes in oligodendrocyte-derived extracellular matrix improves cognition in aged mice.

The paper identifies Etidronate, an FDA-approved drug, as a method to lower ataxin-2 levels in neurons using a CRISPR screen and validates its efficacy in mice.

The paper investigates the phenotypic consequences of RPS25 and RACK1 loss in human cells, finding that RPS25 knockout leads to irreversible resistance traits and gene expression rewiring.

The paper identifies FIS1 as a genetic interactor of C9ORF72 through a synthetic lethal CRISPR screen in human myeloid cells, revealing a role for FIS1 in suppressing inflammatory signaling.

This study shows that LRRK2 modifies α-syn aggregation and spread in both mouse and human models, suggesting potential therapeutic targets for Parkinson's disease.

Genome-wide CRISPR-Cas9 screens in human cells reveal mechanisms and targets for ALS-associated C9orf72 dipeptide repeat protein toxicity.